ZA9610245B - Neuroprotective agents. - Google Patents

Neuroprotective agents.

Info

Publication number
ZA9610245B
ZA9610245B ZA9610245A ZA9610245A ZA9610245B ZA 9610245 B ZA9610245 B ZA 9610245B ZA 9610245 A ZA9610245 A ZA 9610245A ZA 9610245 A ZA9610245 A ZA 9610245A ZA 9610245 B ZA9610245 B ZA 9610245B
Authority
ZA
South Africa
Prior art keywords
neuroprotective agents
neuroprotective
agents
Prior art date
Application number
ZA9610245A
Other languages
English (en)
Inventor
Stephen Shi-Hsun Lin
Katherine Lu Molnar-Kimber
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of ZA9610245B publication Critical patent/ZA9610245B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9610245A 1995-12-07 1996-12-05 Neuroprotective agents. ZA9610245B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
ZA9610245B true ZA9610245B (en) 1998-06-05

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610245A ZA9610245B (en) 1995-12-07 1996-12-05 Neuroprotective agents.

Country Status (23)

Country Link
EP (1) EP0778023B1 (es)
JP (1) JPH09183727A (es)
KR (1) KR970032856A (es)
CN (1) CN1112925C (es)
AR (1) AR008747A1 (es)
AT (1) ATE234095T1 (es)
AU (1) AU700653B2 (es)
BR (1) BR9605895A (es)
CA (1) CA2192298A1 (es)
CZ (2) CZ6498A3 (es)
DE (1) DE69626610T2 (es)
DK (1) DK0778023T3 (es)
ES (1) ES2188730T3 (es)
HU (1) HUP9603370A3 (es)
IL (1) IL119778A (es)
MX (1) MX9606131A (es)
NO (1) NO309966B1 (es)
NZ (1) NZ299888A (es)
PT (1) PT778023E (es)
SI (1) SI0778023T1 (es)
SK (1) SK154796A3 (es)
TW (1) TW427904B (es)
ZA (1) ZA9610245B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
EP1622625A1 (en) * 2003-04-09 2006-02-08 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof
US20070155771A1 (en) * 2003-04-11 2007-07-05 David Rubinsztein Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
MX2007007409A (es) 2004-12-20 2007-07-12 Wyeth Corp Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
ES2380779T3 (es) 2004-12-20 2012-05-18 Wyeth Llc Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
CN102612564B (zh) * 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US20120122913A1 (en) * 2009-07-24 2012-05-17 Institut National De La Recherche Scientifque Combination of curcuminoids and mtor inhibitors for the treatment of tauopathies
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
CN105473131A (zh) 2013-06-05 2016-04-06 法奈克斯公司 用于组合的活性药物成分的稳定口服溶液
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
KR20200088856A (ko) * 2017-11-15 2020-07-23 벤더르빌트 유니버시티 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
NO965238D0 (no) 1996-12-06
KR970032856A (ko) 1997-07-22
HU9603370D0 (en) 1997-01-28
SK154796A3 (en) 1997-09-10
NO965238L (no) 1997-06-09
NO309966B1 (no) 2001-04-30
DE69626610D1 (de) 2003-04-17
AU700653B2 (en) 1999-01-14
BR9605895A (pt) 1998-08-18
HUP9603370A2 (en) 1997-05-28
CN1159915A (zh) 1997-09-24
CZ354496A3 (cs) 1998-03-18
IL119778A0 (en) 1997-03-18
CA2192298A1 (en) 1997-06-08
HUP9603370A3 (en) 1998-12-28
CN1112925C (zh) 2003-07-02
EP0778023A1 (en) 1997-06-11
PT778023E (pt) 2003-06-30
CZ6498A3 (cs) 1998-06-17
JPH09183727A (ja) 1997-07-15
EP0778023B1 (en) 2003-03-12
AU7417896A (en) 1997-06-12
SI0778023T1 (en) 2003-08-31
DK0778023T3 (da) 2003-06-30
ES2188730T3 (es) 2003-07-01
ATE234095T1 (de) 2003-03-15
DE69626610T2 (de) 2003-10-02
TW427904B (en) 2001-04-01
MX9606131A (es) 1997-08-30
IL119778A (en) 1999-07-14
NZ299888A (en) 2001-02-23
AR008747A1 (es) 2000-02-23

Similar Documents

Publication Publication Date Title
ZA9610245B (en) Neuroprotective agents.
ZA967315B (en) Biphenylamides.
MX213417B (es) Fenilpiridazinonas.
ZA961444B (en) Pyrazolylbenzoyl derivatives.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA969648B (en) Nozzle.
ZA961449B (en) Isoxazolylbenzoyl derivatives.
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA965365B (en) Antifungal agents.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA967741B (en) Diarylalkenylamine derivatives.
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA966399B (en) Endothelin-receptor-antagonists.
ZA965494B (en) Therapeutic agents.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA966750B (en) Halogenobenzimidazoles.
ZA967314B (en) Carbamoylcarboxamides.
HUP0004486A3 (en) Neuroprotective agents
ZA964034B (en) N-aminopyridone derivatives.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA965962B (en) Anti-piroplasmotic agent
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols